Volume | 8,605 |
|
|||||
News | - | ||||||
Day High | 0.02075 | Low High |
|||||
Day Low | 0.019 |
Company Name | Stock Ticker Symbol | Market | Type |
---|---|---|---|
Appyea Inc (QB) | APYP | OTCMarkets | Common Stock |
Open Price | Low Price | High Price | Close Price | Prev Close |
---|---|---|---|---|
0.019 | 0.019 | 0.02075 | 0.02075 | 0.02079 |
Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
---|---|---|---|---|---|
3 | 8,605 | $ 0.019038 | $ 164 | - | 0.003 - 0.17 |
Last Trade Time | Type | Quantity | Stock Price | Currency |
---|---|---|---|---|
12:55:40 | 187 | $ 0.02075 | USD |
Appyea Inc (QB) Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
5.68M | 240.32M | 53.61M | 0 | -1.82M | -0.01 | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
Appyea (QB) News
Loading Messages....
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical APYP Price Data
Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 0.024 | 0.0325 | 0.019 | 0.0210659 | 144,107 | -0.00325 | -13.54% |
1 Month | 0.0211 | 0.0363 | 0.019 | 0.0221987 | 65,940 | -0.00035 | -1.66% |
3 Months | 0.03745 | 0.045 | 0.019 | 0.0303076 | 82,554 | -0.0167 | -44.59% |
6 Months | 0.028 | 0.17 | 0.0126 | 0.0241596 | 107,700 | -0.00725 | -25.89% |
1 Year | 0.0121 | 0.17 | 0.003 | 0.0207165 | 284,411 | 0.00865 | 71.49% |
3 Years | 0.0017 | 0.17 | 0.0002 | 0.0029506 | 32,395,261 | 0.01905 | 1,120.59% |
5 Years | 0.0001 | 0.17 | 0.000001 | 0.0020963 | 65,851,523 | 0.02065 | 20,650.00% |
Appyea (QB) Description
APPYEA Inc wholly-owned subsidiary is SleepX is an Israeli research and development company that has developed a unique product for monitoring and treating sleep apnea and snoring. The technology is protected by several international patents and the company plans to start serial production in 2022. The merged entity will focus on further development and commercialization of the products. Its strategy will include continued R&D investment and new initiatives in sales and marketing. |